Polynovo Limited · ASX:PNV
Polynovo — Canaccord Genuity 44th Annual Growth Conference 2024
16 slides from Polynovo's conference presentation, Aug 13, 2024
Slide 1: Canaccord Genuity 44th Annual Growth Conference
For personal use only Canaccord Genuity 44th Annual Growth Conference 13 August 2024 Boston, USA
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or u
Slide 3: Platform technology, underserved market, capital efficient growth and scaling
For personal use only Platform technology Underserved market Capital efficient Growth and Scaling 3
Slide 4: Hyper Growth: Clinician Driven Momentum
Hyper Growth: Clinician Driven Momentum For personal use only CY25: Japan market entry 41 Countries U.K. Germany 50,000+ Patients U.S. 280+ Independent Articles and Abstracts Australia New Zealand FY25: India 117 Patients Enrolled in tenders/reimbursement BARDA Trial Meaningfully Differentiated Pati
Slide 5: NovoSorb: disrupting several attractive addressable markets
NovoSorb®: disrupting several attractive addressable markets For personal use only POLYNOVO FOCUS WORKING WITH ALLIANCES Hernia/other Trauma & Surgical reconstruction (P&R) procedures: Global procedures: 2.5 B 9.4 MM TAM: TAM: $2.6B $3.8B TAM: $1.1B Breast reconstruction TAM: TAM: Global procedures:
Slide 6: Global Strategy on a Page
Global Strategy on a Page: Focused on Burns & Trauma – open to Alliances in Adjacencies For personal use only PolyNovo Focus Burns and Trauma U.S., entering Japan, China Alliance Potential Hernia, Abdominal Wall Reconstruction Acute Care, Ambulatory Care, Intensive Care Acute Care Acute Care Breast
Slide 7: NovoSorb: From Platform Technology to Products
NovoSorb: From Platform Technology to Products For personal use only Burn Surgeons • 1mm, 4mm, 6mm • Immediate STSG Complex • Particulate (contouring, • Antimicrobial Plastic and Reconstruction, Graftable wounds tunnelling) Trauma Surgeons Implantable Surgical • Simple Hernia (mesh • Complex hernia
Slide 8: Scaling Capacity to Support Growth
Scaling Capacity to Support Growth For personal use only Devices Manufactured/Capacity 680,000 New unit in operation (additional 500,000 of capacity per annum) New manufacturing facility 180,000 to be operational in Dec 25, Manufacturing capacity in addition to external 2 manufacturing units in oper
Slide 9: Hyper Growth: Clinician Driven Momentum
Hyper Growth: Clinician Driven Momentum For personal use only FY24 Highlights (Unaudited): • Total revenue including BARDA A$104.8m 200 284 300 • Up 57.5% on STLY A$66.5m 180 215 • Total sales of A$92.0m up 54.5% on STLY A$59.6m 149 200 160 57.5% • U.S. sales of A$68.7m up 49.0% on STLY A$46.1m 140
Slide 10: Next Generation New Standard of Care
For personal use only Next Generation New Standard of Care Platform technology: Graftable & Implantable Capital efficient Growth and Scaling 10
Slide 11: Thank you
For personal use only Thank you
Slide 12: Innovation, Emanating from Frustration with the Existing Standard of Care
Innovation, Emanating from Frustration with the Existing Standard of Care For personal use only The Bali bombing killed 202, critically injured 209. Australian survivors were repatriated to major Burns units for treatment. Large, delayed and colonized wounds required dermal substitutes, but the prev
Slide 13: Disrupting US$2.4B Advanced Skin Substitute Market
Disrupting US$2.4B Advanced Skin Substitute Market For personal use only • Unmet global need for advanced skin substitutes. Underserved • Many products are fraught with issues around tissue origin, complex supply chain, manufacturing, regulatory and licensing category of critical challenges and reli
Slide 14: NovoSorb: Simple. Elegant. Transformative
NovoSorb®: Simple. Elegant. Transformative For personal use only Macro to Micro wounds: • 100% synthetic, maintains integrity over time and resistant to NovoSorb BTM’s matrix organizes a large wound shear forces. (macrowound) into a series of interconnected small wounds • Clinically shown to be robu
Slide 15: Capital Efficient Growth (1H FY 2024)
Capital Efficient Growth (1H FY 2024) 15 For personal use only Revenue, Opex, NPAT excl. non-cash items* 65.6% Operating Leverage • Opex (excl. non-cash) up 42.1% $48.8 vs. revenue growth 65.6% Revenue (m) $42.9 Opex - R&D (m) $4.9 • NPAT excl. non-cash items A$5.7m Opex - other (m) 62.2% vs. STLY l
Slide 16: 1H FY24 Financial Results
1H FY24 Financial Results For personal use only Highlights: • Revenue up 65.6% • Product sales up 54.9% • Operating expenses up 41.3% • Corporate admin and overhead up by 23%; investing disproportionately in R&D, Clinical evidence generation and demand generation • Net profit after tax of A$2.7m (1H
PolyNovo — Canaccord Genuity 44th Annual Growth Conference 2024 on 6ix